

# Christine Jenkins Am., Fracp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8482212/publications.pdf>

Version: 2024-02-01

97  
papers

19,299  
citations

100601

38  
h-index

46524

93  
g-index

98  
all docs

98  
docs citations

98  
times ranked

16022  
citing authors

#	ARTICLE	IF	CITATIONS
1	Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis. <i>Journal of Asthma</i> , 2022, 59, 866-879.	0.9	78
2	Asthma and COVID-19 risk: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 59, 2101209.	3.1	63
3	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	3.1	34
4	Personalized Treatment of Asthma: The Importance of Sex and Gender Differences. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 963-971.e3.	2.0	28
5	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCs Trial. <i>International Journal of COPD</i> , 2022, Volume 17, 273-282.	0.9	0
6	Assessment and diagnosis of chronic dyspnoea: a literature review. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, 10.	1.1	7
7	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 25-33.	2.5	11
8	Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. <i>Lancet Respiratory Medicine</i> , 2022, 10, 497-511.	5.2	121
9	Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. <i>Internal Medicine Journal</i> , 2021, 51, 169-180.	0.5	5
10	The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 57, 2002436.	3.1	4
11	Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1353-1365.	2.5	52
12	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCs randomised controlled trial. <i>European Respiratory Journal</i> , 2021, 57, 2003338.	3.1	24
13	Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2715-2724.e5.	2.0	15
14	Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity. <i>Respirology</i> , 2021, 26, 419-441.	1.3	19
15	Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2090-2101.	2.7	27
16	Epilogue to contemporary perspectives in <sc>COPD</sc>: New Horizons. <i>Respirology</i> , 2021, 26, 742-744.	1.3	0
17	Towards precision in defining COPD exacerbations. <i>Breathe</i> , 2021, 17, 210081.	0.6	4
18	Differences Between Men and Women with Chronic Obstructive Pulmonary Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 443-456.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Social distancing as a strategy to prevent respiratory virus infections. <i>Respirology</i> , 2021, 26, 143-144.	1.3	5
20	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. <i>Biomedicines</i> , 2021, 9, 1837.	1.4	6
21	Too little, too late? The underuse of beta-blockers in COPD needs evidence to address clinical uncertainty. <i>Respirology</i> , 2020, 25, 122-123.	1.3	1
22	Bringing COPD control into the consultation. <i>Respirology</i> , 2020, 25, 1110-1111.	1.3	0
23	Universal face masking in community: Material, design, and considerations—reply. <i>Respirology</i> , 2020, 25, 897-897.	1.3	1
24	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	1.1	33
25	Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. <i>Respiratory Research</i> , 2020, 21, 17.	1.4	16
26	Rationale for universal face masks in public against COVID-19. <i>Respirology</i> , 2020, 25, 678-679.	1.3	50
27	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. <i>Respirology</i> , 2020, 25, 804-815.	1.3	29
28	Cardiovascular Comorbidity in Chronic Lung Disease: Gender Differences. <i>Respiratory Medicine</i> , 2020, , 25-43.	0.1	1
29	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020, 6, 00193-2020.	1.1	14
30	Diagnosis and management of asthma, COPD and asthma-COPD overlap among primary care physicians and respiratory/allergy specialists: A global survey. <i>Clinical Respiratory Journal</i> , 2019, 13, 355-367.	0.6	11
31	ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e023863.	0.8	11
32	Long-Term Azithromycin Reduces <i>Haemophilus influenzae</i> and Increases Antibiotic Resistance in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 309-317.	2.5	121
33	Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 423-435.	0.9	6
34	A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 51-60.e11.	1.5	50
35	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. <i>Respiratory Research</i> , 2019, 20, 4.	1.4	15
36	Experience of acute noninvasive ventilation—insights from “Behind the Mask”: a qualitative study. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, e11-e11.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Real-world study of acute exacerbations of COPD reveals real gaps in care. <i>Respirology</i> , 2018, 23, 644-645.	1.3	1
38	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 337-344.	5.2	149
39	Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 94-103.e15.	1.5	233
40	Perspectives on advance care planning among patients recently requiring non-invasive ventilation for acute respiratory failure: A qualitative study using thematic analysis. <i>Palliative Medicine</i> , 2017, 31, 566-574.	1.3	17
41	Effects of ground-based walking training on daily physical activity in people with COPD: A randomised controlled trial. <i>Respiratory Medicine</i> , 2017, 132, 139-145.	1.3	28
42	The paradoxes of asthma management: time for a new approach?. <i>European Respiratory Journal</i> , 2017, 50, 1701103.	3.1	130
43	Physical activity patterns and clusters in 1001 patients with COPD. <i>Chronic Respiratory Disease</i> , 2017, 14, 256-269.	1.0	56
44	Eliminating asthma deaths: have we stalled?. <i>Lancet</i> , 2017, 390, 915-916.	6.3	1
45	Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2017, 390, 659-668.	6.3	489
46	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. <i>BMC Pulmonary Medicine</i> , 2017, 17, 65.	0.8	6
47	Improving the Management of COPD in Women. <i>Chest</i> , 2017, 151, 686-696.	0.4	86
48	Successes and challenges of COPD management in Australia: reflections on the past and future. <i>Lancet Respiratory Medicine</i> , 2016, 4, 424-426.	5.2	2
49	Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. <i>European Respiratory Review</i> , 2016, 25, 54-64.	3.0	30
50	A score to predict short-term risk of COPD exacerbations (SCOPEX). <i>International Journal of COPD</i> , 2015, 10, 201.	0.9	42
51	Life behind the mask: the patient experience of NIV. <i>Lancet Respiratory Medicine</i> , 2015, 3, 8-10.	5.2	20
52	Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1 $\beta$ . <i>Respiratory Research</i> , 2015, 16, 5.	1.4	66
53	Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2015, 15, 97.	0.8	31
54	Recruiting and retaining general practitioners to a primary care asthma-intervention study in Australia. <i>Australian Journal of Primary Health</i> , 2014, 20, 98.	0.4	6

#	ARTICLE	IF	CITATIONS
55	Is COPD in its age of enlightenment?. Lancet Respiratory Medicine, the, 2014, 2, 960-962.	5.2	0
56	Ground-based walking training improves quality of life and exercise capacity in COPD. European Respiratory Journal, 2014, 44, 885-894.	3.1	56
57	Specialist respiratory physicians' attitudes to and practice of advance care planning in COPD. A pilot study. Respiratory Medicine, 2014, 108, 935-939.	1.3	14
58	Inhaler device technique can be improved in older adults through tailored education: findings from a randomised controlled trial. Npj Primary Care Respiratory Medicine, 2014, 24, 14034.	1.1	56
59	More Than Just Reassurance on Tiotropium Safety. New England Journal of Medicine, 2013, 369, 1555-1556.	13.9	14
60	Characterising the Mechanism of Airway Smooth Muscle $\beta_2$ Adrenoceptor Desensitization by Rhinovirus Infected Bronchial Epithelial Cells. PLoS ONE, 2013, 8, e56058.	1.1	31
61	Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung Disease (BOLD) study. Medical Journal of Australia, 2013, 198, 144-148.	0.8	105
62	Investigating asthma symptoms in primary care. BMJ, The, 2012, 344, e2734-e2734.	3.0	6
63	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Research, 2011, 12, 38.	1.4	58
64	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research, 2011, 12, 71.	1.4	60
65	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322.	2.5	157
66	Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6.	1.5	219
67	Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465.	0.4	240
68	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59.	1.4	287
69	Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A double-blind randomised controlled trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 39-45.	2.5	21
70	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	13.9	2,963
71	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 532-555.	2.5	5,801
72	Efficacy and safety of high-dose budesonide/formoterol (SymbicortR) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respiriology, 2006, 11, 276-286.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Distinguishing asthma and chronic obstructive pulmonary disease: why, why not and how?. Medical Journal of Australia, 2005, 183, S35-7.	0.8	18
74	Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ: British Medical Journal, 2004, 328, 434.	2.4	365
75	GM-CSF therapy in pulmonary alveolar proteinosis. Thorax, 2002, 57, 837-837.	2.7	17
76	Impact of Inhaled Salmeterol/Fluticasone Propionate Combination Product versus Budesonide on the Health-Related Quality of Life of Patients with Asthma. Treatments in Respiratory Medicine, 2002, 1, 435-440.	1.4	35
77	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1256-1276.	2.5	5,055
78	Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 406-412.	2.5	302
79	Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection with <i>Chlamydia pneumoniae</i> . American Journal of Respiratory and Critical Care Medicine, 2001, 164, 536-541.	2.5	160
80	Serological evidence of infection with <i>Chlamydia pneumoniae</i> is related to the severity of asthma. European Respiratory Journal, 2000, 15, 254.	3.1	133
81	Optimal asthma control, starting with high doses of inhaled budesonide. European Respiratory Journal, 2000, 16, 226.	3.1	150
82	Long-acting $\beta_2$ -agonists: the new symptom controllers for asthma. Medical Journal of Australia, 1999, 171, 255-258.	0.8	1
83	Diurnal variability—time to change asthma guidelines?. BMJ: British Medical Journal, 1999, 319, 45-47.	2.4	41
84	Differences between asthma exacerbations and poor asthma control. Lancet, The, 1999, 353, 364-369.	6.3	245
85	Standardization of ambulatory peak flow monitoring: the importance of recent $\beta_2$ -agonist inhalation. European Respiratory Journal, 1998, 12, 309-314.	3.1	15
86	Pitfalls in processing home electronic spirometric data in asthma. European Respiratory Journal, 1998, 12, 853-858.	3.1	34
87	Airway Responsiveness in Asthma: Bronchial Challenge with Histamine and 4.5% Sodium Chloride Before and After Budesonide. Allergy and Asthma Proceedings, 1997, 18, 7-14.	1.0	47
88	Asthma mortality: where is it going?. Medical Journal of Australia, 1996, 164, 391-392.	0.8	12
89	$\beta_2$ agonists in asthma*. Australian and New Zealand Journal of Medicine, 1995, 25, 358-361.	0.5	2
90	Acute Effect of Sodium Cromoglycate on Airway Narrowing Induced by 4.5 Percent Saline Aerosol. Chest, 1994, 105, 673-680.	0.4	48

#	ARTICLE	IF	CITATIONS
91	Assessment of Bronchial Responsiveness as a Guide to Prognosis and Therapy in Asthma. Medical Clinics of North America, 1990, 74, 753-765.	1.1	42
92	Effect of prednisone and beclomethasone dipropionate on airway responsiveness in asthma: a comparative study.. Thorax, 1988, 43, 378-384.	2.7	120
93	Long term study of the effect of sodium cromoglycate on non-specific bronchial hyperresponsiveness.. Thorax, 1987, 42, 664-669.	2.7	21
94	The role of alpha and beta adrenoceptors in airway hyperresponsiveness to histamine. Journal of Allergy and Clinical Immunology, 1985, 75, 364-372.	1.5	7
95	Experience with allergic bronchopulmonary aspergillosis: some unusual features. Clinical and Experimental Allergy, 1984, 14, 21-28.	1.4	6
96	Pulmonary Cryptococcosis: Atypical Results in the Serum Test for Cryptococcal Antigen. Australian and New Zealand Journal of Medicine, 1982, 12, 527-530.	0.5	2
97	Comparison of Ipratropium Bromide and Salbutamol by Aerosolized Solution. Australian and New Zealand Journal of Medicine, 1981, 11, 513-516.	0.5	27